Sprout Pharmaceuticals Inc.’s appeal to FDA on its rejected female sexual dysfunction drug flibanserin resulted in a request for three small, new safety studies, but not the efficacy work that had been suggested in a “complete response” letter for the filing, according to the company.
Following a submission in March 2013, FDA issued a CRL for flibanserin in October of that year requesting additional efficacy and safety work
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?